StockData
Braveheart Bio, Inc. logo

Braveheart Bio, Inc. (BRVE) stock

BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.78−0.71 (-3.64%)

Close on Nov 17, 2026Market cap $1.69BP/E –Yield –

Braveheart Bio enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Braveheart Bio's enterprise value was $34.67M on Nov 11, 2026.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$34.67M–

More Braveheart Bio figures

See a number that looks wrong?